Organogenesis Q2 Revenue Plunges 58%, Loss Widens to $96M; Guidance Slashed
ORGO is trading near its 52-week low of $2.04 (14% above the low).
Summary
Organogenesis Q2 revenue fell 58% to $42.8M, net loss widened to $96.3M, and full-year guidance was cut sharply. Cash dropped to $46.8M, raising urgent liquidity concerns.
Key Events · Earnings and Guidance · ORGO
-
Revenue Collapse
Q2 2026 net revenue of $42.8M, down 58% YoY from $100.8M, driven by a 61% drop in Advanced Wound Care products.
-
Massive Net Loss
Net loss of $96.3M ($0.77/share) vs. $9.4M loss in Q2 2025; adjusted EBITDA loss of $34.4M.
-
Cash Burn Accelerates
Cash and equivalents fell to $46.8M at June 30, 2026, from $94.3M at year-end 2025, with no debt outstanding.
-
Full-Year Guidance Slashed
2026 revenue guidance lowered to $179M-$215M, implying a 62-68% decline from 2025, with a slower recovery expected.
Analysis · ORGO · Life Sciences
A disastrous second quarter saw revenue collapse 58% year-over-year to $42.8 million, while the net loss ballooned to $96.3 million from $9.4 million a year ago. Nearly half the company's cash was consumed in six months, leaving just $46.8 million at quarter-end. Management responded by slashing full-year revenue guidance to $179–$215 million, implying a 62–68% decline from 2025, and now anticipates a much slower recovery than previously forecast. The results underscore the devastating impact of CMS reimbursement changes on the core Advanced Wound Care business, which suffered a 61% revenue drop. With cash dwindling and losses accelerating, mounting pressure falls on the company to secure additional capital or dramatically cut costs to extend its runway.
At the time of this filing, ORGO was trading at $2.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $310.1M. The 52-week trading range was $2.04 to $7.08. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.